SOURCE: Elsevier Business Intelligence

Elsevier Business Intelligence

February 01, 2010 09:00 ET

Multinational Medtech Companies and Savvy Medtech Investors Will Reveal Investment, M&A and Partnering Preferences at Elsevier's 'Medical Device Investor Day' in Paris on April 28th, 2010

Special Event Precedes 'IN3 Europe', One of Europe's Largest Annual Strategic Partnership and Investment Meeting

PARIS--(Marketwire - February 1, 2010) - Elsevier Business Intelligence, the medtech industry's leading strategic partner and investment conference-organizer, announced today that it will host 'Medical Device Investor Day' on April 28th, 2010, at The Marriott Rive Gauche, Paris. This special event is the prelude to 'IN3 Europe', also being held at The Marriott Rive Gauche, on April 29-30, 2010.

Medical Device Investor Day will appeal to medtech innovators who are interested in what medical technology investment leaders are thinking, doing, and planning. Venture and corporate investment professionals will speak about what interests them most among medical device technologies: therapeutic areas, products, and geographic markets. They will also discuss partnering opportunities, how to maximize visibility in front of large-company investors, and their expected appetite for M&A in the near term. Participants from the podium will include Edmond de Rothschild Investment Partners, Boston Scientific, Sofinnova Partners, Abingworth LLP, Earlybird Venture Capital, Sofimac Partners SA, NBGI Ventures, De Novo Ventures, Index Ventures, Ysios Capital, Delta Partners and Wellington Partners, among others.

"Medical Device Investor Day in Paris will draw early-, mid-, and late-stage medtech innovators who want to meet some of the most successful device dealmakers in financing, partnering, and M&A," said David Cassak, Editor and Managing Director at Elsevier Business Intelligence. "Emerging and start-up medtech companies continue to face extreme competition for a restricted amount of available capital funding. This makes Medical Device Investor Day the perfect venue for emerging companies to meet and impress potential investors from many of the top-tier device companies and discerning healthcare investment firms from Europe and the U.S."

Medical Device Investor Day will be followed by IN3 Europe on April 29-30, also at The Marriott Rive Gauche. IN3 Europe is one of the largest annual strategic partnership and investment meeting in Europe for senior-level medical technology executives. An audience of several hundred, including venture capital firms and other investors in the medtech industry, is expected to attend IN3 Europe to hear from more than 70 emerging medical technology companies seeking funding and/or strategic partnerships.

For more information, please contact: Kristy Grimes at +1-480-985-9512 or Kayleen Kell at +1-888-290-2225, or email IN3@Elsevier.com.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (www.thelancet.com) and Cell (www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect (www.sciencedirect.com), Scopus (www.scopus.com), Reaxys (www.reaxys.com), MD Consult (www.mdconsult.com) and Nursing Consult (www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (www.scival.com) and MEDai's Pinpoint Review (www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier (www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (www.reedelsevier.com), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Contact Information